Cargando…

Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies

Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular p...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shengkang, Wang, Xinyu, Wang, Yu, Wang, Yajing, Fang, Chenglong, Wang, Yazhuo, Chen, Sifei, Chen, Runkai, Lei, Tao, Zhang, Yuchen, Xu, Xinjie, Li, Yuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163813/
https://www.ncbi.nlm.nih.gov/pubmed/37149643
http://dx.doi.org/10.1186/s12943-023-01783-1
_version_ 1785037961989980160
author Huang, Shengkang
Wang, Xinyu
Wang, Yu
Wang, Yajing
Fang, Chenglong
Wang, Yazhuo
Chen, Sifei
Chen, Runkai
Lei, Tao
Zhang, Yuchen
Xu, Xinjie
Li, Yuhua
author_facet Huang, Shengkang
Wang, Xinyu
Wang, Yu
Wang, Yajing
Fang, Chenglong
Wang, Yazhuo
Chen, Sifei
Chen, Runkai
Lei, Tao
Zhang, Yuchen
Xu, Xinjie
Li, Yuhua
author_sort Huang, Shengkang
collection PubMed
description Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular patterns at unprecedented resolution, have greatly advanced our understanding of immunology and oncology. In this review, we summarize the recent applications of single-cell sequencing technologies in CAR T-cell therapy, including the biological characteristics, the latest mechanisms of clinical response and adverse events, promising strategies that contribute to the development of CAR T-cell therapy and CAR target selection. Generally, we propose a multi-omics research mode to guide potential future research on CAR T-cell therapy.
format Online
Article
Text
id pubmed-10163813
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101638132023-05-07 Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies Huang, Shengkang Wang, Xinyu Wang, Yu Wang, Yajing Fang, Chenglong Wang, Yazhuo Chen, Sifei Chen, Runkai Lei, Tao Zhang, Yuchen Xu, Xinjie Li, Yuhua Mol Cancer Review Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular patterns at unprecedented resolution, have greatly advanced our understanding of immunology and oncology. In this review, we summarize the recent applications of single-cell sequencing technologies in CAR T-cell therapy, including the biological characteristics, the latest mechanisms of clinical response and adverse events, promising strategies that contribute to the development of CAR T-cell therapy and CAR target selection. Generally, we propose a multi-omics research mode to guide potential future research on CAR T-cell therapy. BioMed Central 2023-05-06 /pmc/articles/PMC10163813/ /pubmed/37149643 http://dx.doi.org/10.1186/s12943-023-01783-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Huang, Shengkang
Wang, Xinyu
Wang, Yu
Wang, Yajing
Fang, Chenglong
Wang, Yazhuo
Chen, Sifei
Chen, Runkai
Lei, Tao
Zhang, Yuchen
Xu, Xinjie
Li, Yuhua
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
title Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
title_full Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
title_fullStr Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
title_full_unstemmed Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
title_short Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
title_sort deciphering and advancing car t-cell therapy with single-cell sequencing technologies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163813/
https://www.ncbi.nlm.nih.gov/pubmed/37149643
http://dx.doi.org/10.1186/s12943-023-01783-1
work_keys_str_mv AT huangshengkang decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT wangxinyu decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT wangyu decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT wangyajing decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT fangchenglong decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT wangyazhuo decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT chensifei decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT chenrunkai decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT leitao decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT zhangyuchen decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT xuxinjie decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies
AT liyuhua decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies